Tag Archives: BCI Pioneers Coalition

Virtual panel discussion: Canadian Strategies for Responsible Neurotechnology Innovation on May 16, 2023

The Canadian Science Policy Centre (CSPC) sent a May 11, 2023 notice (via email) about an upcoming event but first, congratulations (Bravo!) are in order,

The Science Meets Parliament [SMP] Program 2023 is now complete and was a huge success. 43 Delegates from across Canada met with 62 Parliamentarians from across the political spectrum on the Hill on May 1-2, 2023.

The SMP Program is championed by CSPC and Canada’s Chief Science Advisor, Dr. Mona Nemer [through the Office of the Chief Science Advisor {OCSA}].

This Program would not have been possible without the generous support of our sponsors: The Royal Military College of Canada, The Stem Cell Network, and the University of British Columbia.

There are 443 seats in Canada’s Parliament with 338 in the House of Commons and 105 in the Senate and 2023 is the third time the SMP programme has been offered. (It was previously held in 2018 and 2022 according to the SMP program page.)

The Canadian programme is relatively new compared to Australia where they’ve had a Science Meets Parliament programme since 1999 (according to a March 20, 2017 essay by Ken Baldwin, Director of Energy Change Institute at Australian National University for The Conversation). The Scottish have had a Science and the Parliament programme since 2000 (according to this 2022 event notice on the Royal Society of Chemistry’s website).

By comparison to the other two, the Canadian programme is a toddler. (We tend not to recognize walking for the major achievement it is.) So, bravo to the CSPC and OCSA on getting 62 Parliamentarians to make time in their schedules to meet a scientist.

Responsible neurotechnology innovation?

From the Canadian Strategies for Responsible Neurotechnology Innovation event page on the CSPC website,

Advances in neurotechnology are redefining the possibilities of improving neurologic health and mental wellbeing, but related ethical, legal, and societal concerns such as privacy of brain data, manipulation of personal autonomy and agency, and non-medical and dual uses are increasingly pressing concerns [emphasis mine]. In this regard, neurotechnology presents challenges not only to Canada’s federal and provincial health care systems, but to existing laws and regulations that govern responsible innovation. In December 2019, just before the pandemic, the OECD [Organisation for Economic Cooperation and Development] Council adopted a Recommendation on Responsible Innovation in Neurotechnology. It is now urging that member states develop right-fit implementation strategies.

What should these strategies look like for Canada? We will propose and discuss opportunities that balance and leverage different professional and governance approaches towards the goal of achieving responsible innovation for the current state of the art, science, engineering, and policy, and in anticipation of the rapid and vast capabilities expected for neurotechnology in the future by and for this country.

Link to the full OECD Recommendation on Responsible Innovation in Neurotechnology

Date: May 16 [2023]

Time: 12:00 pm – 1:30 pm EDT

Event Category: Virtual Session [on Zoom]

Registration Page: https://us02web.zoom.us/webinar/register/WN_-g8d1qubRhumPSCQi6WUtA

The panelists are:

Dr. Graeme Moffat
Neurotechnology entrepreneur & Senior Fellow, Munk School of Global Affairs & Public Policy [University of Toronto]

Dr. Graeme Moffat is a co-founder and scientist with System2 Neurotechnology. He previously was Chief Scientist and VP of Regulatory Affairs at Interaxon, Chief Scientist with ScienceScape (later Chan-Zuckerberg Meta), and a research engineer at Neurelec (a division of Oticon Medical). He served as Managing Editor of Frontiers in Neuroscience, the largest open access scholarly journal series in the field of neuroscience. Dr. Moffat is a Senior Fellow at the Munk School of Global Affairs and Public Policy and an advisor to the OECD’s neurotechnology policy initiative.

Professor Jennifer Chandler
Professor of Law at the Centre for Health Law, Policy and Ethics, University of Ottawa

Jennifer Chandler is Professor of Law at the Centre for Health Law, Policy and Ethics, University of Ottawa. She leads the “Neuroethics Law and Society” Research Pillar for the Brain Mind Research Institute and sits on its Scientific Advisory Council. Her research focuses on the ethical, legal and policy issues in brain sciences and the law. She teaches mental health law and neuroethics, tort law, and medico-legal issues. She is a member of the advisory board for CIHR’s Institute for Neurosciences, Mental Health and Addiction (IMNA) and serves on international editorial boards in the field of law, ethics and neuroscience, including Neuroethics, the Springer Book Series Advances in Neuroethics, and the Palgrave-MacMillan Book Series Law, Neuroscience and Human Behavior. She has published widely in legal, bioethical and health sciences journals and is the co-editor of the book Law and Mind: Mental Health Law and Policy in Canada (2016). Dr. Chandler brings a unique perspective to this panel as her research focuses on the ethical, legal and policy issues at the intersection of the brain sciences and the law. She is active in Canadian neuroscience research funding policy, and regularly contributes to Canadian governmental policy on contentious matters of biomedicine.

Ian Burkhart
Neurotech Advocate and Founder of BCI [brain-computer interface] Pioneers Coalition

Ian is a C5 tetraplegic [also known as quadriplegic] from a diving accident in 2010. He participated in a ground-breaking clinical trial using a brain-computer interface to control muscle stimulation. He is the founder of the BCI Pioneers Coalition, which works to establish ethics, guidelines and best practices for future patients, clinicians, and commercial entities engaging with BCI research. Ian serves as Vice President of the North American Spinal Cord Injury Consortium and chairs their project review committee. He has also worked with Unite2Fight Paralysis to advocate for $9 million of SCI research in his home state of Ohio. Ian has been a Reeve peer mentor since 2015 and helps lead two local SCI networking groups. As the president of the Ian Burkhart Foundation, he raises funds for accessible equipment for the independence of others with SCI. Ian is also a full-time consultant working with multiple medical device companies.

Andrew Atkinson
Manager, Emerging Science Policy, Health Canada

Andrew Atkinson is the Manager of the Emerging Sciences Policy Unit under the Strategic Policy Branch of Health Canada. He oversees coordination of science policy issues across the various regulatory and research programs under the mandate of Health Canada. Prior to Health Canada, he was a manager under Environment Canada’s CEPA new chemicals program, where he oversaw chemical and nanomaterial risk assessments, and the development of risk assessment methodologies. In parallel to domestic work, he has been actively engaged in ISO [International Organization for Standardization and OECD nanotechnology efforts.

Andrew is currently a member of the Canadian delegation to the OECD Working Party on Biotechnology, Nanotechnology and Converging Technologies (BNCT). BNCT aims to contribute original policy analysis on emerging science and technologies, such as gene editing and neurotechnology, including messaging to the global community, convening key stakeholders in the field, and making ground-breaking proposals to policy makers.

Professor Judy Illes
Professor, Division of Neurology, Department of Medicine, Faculty of Medicine, UBC [University of British Columbia]

Dr. Illes is Professor of Neurology and Distinguished Scholar in Neuroethics at the University of British Columbia. She is the Director of Neuroethics Canada, and among her many leadership positions in Canada, she is Vice Chair of the Canadian Institutes of Health Research (CIHR) Advisory Board of the Institute on Neuroscience, Mental Health and Addiction (INMHA), and chair of the International Brain Initiative (www.internationalbraininitiative.org; www.canadianbrain.ca), Director at Large of the Canadian Academy of Health Sciences, and a member of the Board of Directors of the Council of Canadian Academies.

Dr. Illes is a world-renown expert whose research, teaching and outreach are devoted to ethical, legal, social and policy challenges at the intersection of the brain sciences and biomedical ethics. She has made ground breaking contributions to neuroethical thinking for neuroscience discovery and clinical translation across the life span, including in entrepreneurship and in the commercialization of health care. Dr. Illes has a unique and comprehensive overview of the field of neurotechnology and the relevant sectors in Canada.

One concern I don’t see mentioned is bankruptcy (in other words, what happens if the company that made your neural implant goes bankrupt?) either in the panel description or in the OECD recommendation. My April 5, 2022 posting “Going blind when your neural implant company flirts with bankruptcy (long read)” explored that topic and while many of the excerpted materials present a US perspective, it’s easy to see how it could also apply in Canada and elsewhere.

For those of us on the West Coast, this session starts at 9 am. Enjoy!

*June 20, 2023: This sentence changed (We tend not to recognize that walking for the major achievement it is.) to We tend not to recognize walking for the major achievement it is.